Merck to Hold Investor Briefing at 2016 ASCO Annual Meeting
Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that Dr. Roger M. Perlmutter, president,
Merck Research Laboratories, will present an overview of the company’s oncology program at the 52nd Annual Meeting of the American
Society of Clinical Oncology (ASCO) in Chicago on June 6, 2016 at 5:45 p.m. CDT (6:45 p.m. EDT).
Investors, analysts, members of the media and the general public are invited to listen to a live audio webcast of the
presentation at http://investors.merck.com/investors/webcasts-and-presentations/default.aspx or by dialing (866) 486-2604 and
using ID code number 21794108.
About Merck
For 125 years, Merck has been a global health care leader working to help the world be well. Merck is known as MSD outside the
United States and Canada. Through our prescription medicines, vaccines, biologic therapies, and animal health products, we work
with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to
increasing access to health care through far-reaching policies, programs and partnerships. For more information, visit www.merck.com and connect with us on Twitter, Facebook, YouTube and LinkedIn. You can also follow our Twitter conversation at $MRK.
Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA
This news release of Merck & Co., Inc., Kenilworth, N.J., USA (the “company”) includes “forward-looking statements” within
the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based
upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There
can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that
they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties
materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors,
including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care
legislation in the United States and internationally; global trends toward health care cost containment; technological advances,
new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory
approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial
instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other
protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information,
future events or otherwise. Additional factors that could cause results to differ materially from those described in the
forward-looking statements can be found in the company’s 2015 Annual Report on Form 10-K and the company’s other filings with the
Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).
Merck
Media:
Lainie Keller, (908) 236-5036
or
Investor:
Teri Loxam, (908) 740-1986
or
Justin Holko, (908) 740-1879
View source version on businesswire.com: http://www.businesswire.com/news/home/20160601006595/en/